Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer

October 12, 2016
C-13 ARGO
Colon Cancer
Alexander Hantel, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

To test whether the oral (by mouth) drug, regorafenib, is effective in reducing the risk of the colon cancer recurring after patients have received adjuvant chemotherapy.

Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)

https://clinicaltrials.gov/ct2/show/NCT02664077

  • Adenocarcinoma of the colon Stage IIIB or IIIC
  • Interval between completion of standard adjuvant chemotherapy and randomization must be < 60 days
10 years
Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072